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Lysosomes degrade cellular components sequestered by autophagy
or extracellular material internalized by endocytosis and phagocy-
tosis. The macromolecule building blocks released by lysosomal
hydrolysis are then exported to the cytosol by lysosomal trans-
porters, which remain undercharacterized. In this study, we designed
an in situ assay of lysosomal amino acid export based on the tran-
scription factor EB (TFEB), a master regulator of lysosomal biogenesis
that detects lysosomal storage. This assay was used to screen candi-
date lysosomal transporters, leading to the identification of sodium-
coupled neutral amino acid transporter 7 (SNAT7), encoded by the
SLC38A7 gene, as a lysosomal transporter highly selective for gluta-
mine and asparagine. Cell fractionation confirmed the lysosomal lo-
calization of SNAT7, and flux measurements confirmed its substrate
selectivity and showed a strong activation by the lysosomal pH gra-
dient. Interestingly, gene silencing or editing experiments revealed
that SNAT7 is the primary permeation pathway for glutamine across
the lysosomal membrane and it is required for growth of cancer cells
in a low free-glutamine environment, when macropinocytosis and
lysosomal degradation of extracellular proteins are used as an alter-
native source of amino acids. SNAT7 may, thus, represent a novel
target for glutamine-related anticancer therapies.
lysosome | transporter | glutamine | cell nutrition | cancer
Lysosomes are single-membrane organelles acting as majorrecycling sites in eukaryotic cells. They are equipped with
acidic hydrolases and degrade aged or damaged macromolecules
and organelles sequestered or internalized by the autophagy, en-
docytosis, and phagocytosis pathways. The macromolecule building
blocks (amino acids, sugars, nucleosides, etc.) released by these
hydrolases are then exported to the cytosol by lysosomal trans-
porters for reuse in cellular metabolism. In addition to this well-
known catabolic role, lysosomes have been involved in other cel-
lular functions, such as lysosomal cell death (1), cell membrane
repair (2), and cell homeostasis, in which they act as signaling hubs
for activation of the mechanistic target of rapamycin complex 1
(mTORC1), a master regulator of growth and metabolism (3).
Lysosomes also participate in a transcriptional feedback loop that
adapts lysosomal degradation to cellular needs (4).
Finally, lysosomes, especially lysosomal transporters, also play a
role in cell nutrition by providing an alternative route to nutrients
and micronutrients that do not readily cross the plasma mem-
brane. For instance, cellular uptake of cobalamin, which tightly
binds transcobalamin II in extracellular fluids, involves receptor-
mediated endocytosis of the transcobalamin/cobalamin complex,
degradation of transcobalamin in the lysosomal lumen, and lyso-
somal export of free cobalamin through a process requiring the
membrane proteins ABCD4 and LMBD1 (5–7). Nutrients may
also be internalized without membrane receptors by fluid-phase
endocytosis (pinocytosis) or macropinocytosis. For instance, ex-
ternal free sialic acids enter cells through pinocytosis and lysosomal
export by the sialic acid transporter sialin (8, 9). This two-step
indirect route accounts for the metabolic incorporation of the
dietary, nonhuman sialic acid N-glycolylneuraminic acid into human
cell glycans (10). Recently, lysosomes have been similarly shown to
participate in an “opportunistic” nutrition route of cancer cells when
free amino acids are scarce in their environment (11). Under such
conditions, lysosomal degradation of internalized extracellular pro-
teins and lysosomal amino acid export can compensate for the lack
of free amino acid uptake at the plasma membrane. For instance,
Ras-activated cancer cells acquire glutamine, an amino acid essen-
tial to their proliferation, through macropinocytosis of extracellular
proteins (12).
In this study, we investigated the molecular and cellular func-
tions of a poorly characterized member of the solute carrier 38
(SLC38) family, also known as the sodium-coupled neutral amino
acid transporter (SNAT) family. This family includes 11 members
in the human genome, which, for the best characterized, are di-
vided in two subgroups: system A and system N transporters. Sys-
tem A transporters (SNAT1, SNAT2, and SNAT4) have a broad
selectivity for neutral amino acids, which they cotransport with one
Na+. System N transporters (SNAT3, SNAT5, and possibly
SNAT8) prefer glutamine, asparagine, and histidine over small
neutral amino acids, and their ion-coupling mechanism is more
complex, with an antiport of proton in addition to the cotransport
of Na+ and the coexistence of multiple transport modes (13, 14).
SNAT9, also known as SLC38A9, stands out in this family
because it was recently characterized as a slow, broadly selec-
tive amino acid transporter involved in amino acid-sensing and
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signaling to mTORC1 at the lysosomal membrane (15, 16). In
particular, SNAT9 interacts with the Ragulator/Rag GTPase com-
plex in an amino acid-dependent manner, and mTORC1 fails to be
activated by amino acids, especially arginine, in its absence. It was
thus suggested that SNAT9 acts as a transceptor, that is, a
transporter-like protein with receptor function (17), rather than as a
genuine amino acid transporter (15, 16, 18).
In a recent study of the lysosomal proteome, we unambiguously
detected SNAT7 in the lysosomal membrane (19). SNAT9 was
also detected in a lysosome-specific manner in that study, yet only
in a single biological replicate of three, preventing its inclusion in
our proteome list. Expression of a recombinant SNAT7 fused to
GFP colocalized with LAMP1, a marker of late endosomes and
lysosomes, thus corroborating our proteomic finding (19). In this
study, we establish the lysosomal localization of the native protein
and show that SNAT7 transports glutamine and asparagine, but
not other amino acids, in an acidic pH-stimulated manner, and
that it represents the primary permeation pathway for these amino
acids across the lysosomal membrane. Moreover, we show that
SNAT7 is required for nutrition of cancer cells in a low free-
glutamine environment, when macropinocytosis and lysosomal
degradation of extracellular proteins are used as an alternative
source of amino acids to sustain cell growth.
Results
A TFEB-Based Live-Cell Assay of Lysosomal Amino Acid Transporters.
To screen for potential lysosomal amino acid transporters, we
developed an assay based on the indirect detection of lysosomal
stress induced by amino acid overload in live cells. Lysosomal
stress can be monitored using the master transcription factor EB
(TFEB), which regulates lysosomal biogenesis and autophagy, and
adapts them to degradative needs of eukaryotic cells (20). Under
unstressed, nutrient-replete conditions, TFEB is phosphorylated
by mTORC1 at the lysosomal surface, resulting in its cytosolic
retention and inhibition (21–23). However, when macromolecules
or small molecules accumulate in lysosomes, TFEB is dephos-
phorylated and translocated to the nucleus, where it activates ly-
sosomal and autophagy genes (4, 20). We, thus, reasoned that
artificial overload of lysosomes with a specific amino acid in live
cells should induce nuclear translocation of TFEB. Because most
lysosomal metabolite transporters export their substrates to the
cytosol, overexpression of a cognate transporter for the tested
amino acid should reduce lysosomal overload and, consequently,
reduce nuclear translocation of TFEB (Fig. 1A).
To overload lysosomes artificially with amino acids, we used an
old biochemical trick that consists of the application of amino acid
esters. Esters readily permeate biological membranes, and ester
hydrolysis in the acidic, hydrolase-rich lysosome generates a free
amino acid build-up within its lumen (24). This approach has
traditionally been used with subcellular fractions. However, we
recently observed that it can significantly load lysosomes with
amino acids in live cells as well (figure 6F of ref. 25), indicating
that a significant proportion of uncleaved ester reaches lysosomes
despite the presence of cytosolic esterases.
We, thus, applied diverse amino acid esters to HeLa cells
transiently expressing a monomeric red fluorescent protein
(mRFP)/TFEB fusion protein and tested whether they induce
lysosomal stress. The mRFP-TFEB intracellular distribution was
classified in three categories, nuclear, cytosolic, and mixed, to pro-
vide a semiquantitative measurement of lysosomal stress (Fig. 1B).
Several amino acid esters activated mRFP-TFEB in a dose-
dependent manner (representative examples are shown in Fig.
S1). A concentration-inducing nuclear translocation of mRFP-
TFEB (nuclear +mixed distributions) in about 40% of cells was
selected for each ester to detect whether additional treatments
alter lysosomal overload with a good sensitivity. For glutamine,
we used an ester made with an alcohol group (tert-butanol)
more hydrophobic than methanol to reach this level of lyso-
somal stress (Fig. S1).
Next, we coexpressed known lysosomal transporters with mRFP-
TFEB and tested whether they protect cells from the artificial
amino acid overload. Plasmid transfection induced transient nu-
clear translocation of mRFP-TFEB (which vanished after 48 h),
highlighting the sensitivity of the mTORC1/TFEB pathway to di-
verse internal cues. We used a well-targeted, inactive lysosomal
sugar transporter [human sialin P334R (9)] as a negative control to
address the possibility that lysosomal membrane protein over-
expression might also induce lysosomal stress independent of any
luminal overload. Interestingly, these experiments showed that
overexpression of the lysosomal amino acid exporters LYAAT1
(26) and PQLC2 (25) selectively reduced the lysosomal stress
caused by esters of their cognate amino acids (alanine and lysine,
respectively), but not by esters of nontranslocated amino acids (Fig.
1B). In contrast, the inactive lysosomal sugar transporter had no
effect in any tested condition (Fig. 1B). Our TFEB-based live-cell
assay, thus, successfully detects the build-up of amino acids in ly-
sosomes and, conversely, their depletion by lysosomal transporters.
We used this assay to screen orphan lysosomal membrane pro-
teins or poorly characterized lysosomal transporters for amino acid
transport. In a recent proteomic study, we identified several pro-
tein candidates, including SNAT7, a poorly characterized member
of the SLC38 transporter family (19). A set of 11 tractable amino
acid esters was screened against SNAT7 in our assay to identify its
putative substrates. HeLa cells expressing PQLC2 provided a
positive control (lysine methyl ester) and negative controls (other
esters) in these experiments. Fig. 1C shows the mean outcome of
three independent experiments. As expected, PQLC2 reduced the
lysosomal overload of lysine, but not of neutral and anionic amino
acids, in agreement with the cationic amino acid selectivity of its
transport function (25, 27). In contrast, SNAT7 overexpression
selectively decreased the lysosomal stress induced by asparagine
and glutamine esters, but not by other amino acid esters (Fig. 1C).
We concluded that SNAT7 selectively exports asparagine and
glutamine from the lysosome.
Subcellular Localization of Native SNAT7 in HeLa Cells. In our pre-
vious study, we validated the selective proteomic detection in
lysosome-enriched fractions by showing that a recombinant
construct (EGFP-SNAT7) colocalizes with late endosomes and
lysosomes in HeLa cells (19). To get additional evidence for the
native protein, we examined its intracellular distribution by
subcellular fractionation. Human SNAT7 (hSNAT7) was de-
tected on immunoblots using a polyclonal antibody directed
against the 53 first amino acids (HPA041777; Atlas Antibodies).
In HeLa cell homogenates, HPA041777 immunoreactivity was
mostly associated with a 40-kDa band (Fig. 2B). To confirm the
identity of this band, we inactivated the SLC38A7 gene, which
encodes SNAT7, in HeLa cells using the CRISPR/Cas9 nickase
method for genome editing (28). In agreement with our HeLa
clone genomic sequences, homozygous disruption of SLC38A7
selectively abolished the 40-kDa band, showing that it corre-
sponds to native SNAT7 (Fig. 2 A and B).
We next analyzed the behavior of the SNAT7 band on sub-
cellular fractionation, because the antibody could not be used to
detect endogenous levels of the protein by immunofluorescence
(Fig. S2). HeLa cells were first subjected to a classical differential
centrifugation method (29). In this protocol (Fig. 2C), SNAT7 was
strongly enriched in the L fraction (enriched in lysosomes) with
only minor signal in the M fraction (which contains the bulk of
mitochondria) and the P fraction (in which most of the peroxi-
some and microsome populations are recovered). Moreover, the
quantitative distribution profile of SNAT7 was very similar to
the profile of the lysosomal marker, and clearly distinct from the
profiles of other cell compartments, including the plasma mem-
brane (Fig. 2D and Fig. S3). Fractions M and L were then pooled


































and further fractionated using isopycnic centrifugation on a linear
sucrose density gradient. This technique showed that SNAT7
perfectly codistributes with the lysosomal marker, but not with
mitochondrial, endoplasmic reticulum, and peroxisomal markers
(Fig. 2D and Fig. S3). Plasma membrane vesicles overlapped with
lysosomes in this gradient. However, most of them were discarded
from the pooled M + L fractions, and the contrasting profiles of
SNAT7 and the plasma membrane marker in the differential
centrifugation protocol indicate that the plasma membrane pool
of SNAT7, if any, is, at most, a minor part of the total pool. We
concluded that native SNAT7 is a resident lysosomal protein.
SNAT7 Is the Primary Permeation Pathway for Glutamine and
Asparagine Across the Lysosomal Membrane. An earlier study
reported that SNAT7 is a promiscuous plasma membrane trans-
porter that recognizes a high diversity of amino acids, including
alanine, arginine, and glutamine at least (30). However, we could
not replicate these data, and we could not measure reliable uptake
signals when SNAT7-expressing Xenopus oocytes were incubated
in an acidic medium to mimic the environment faced by SNAT7 in
the lysosomal membrane. Artificial redirection to the cell surface
by mutation of lysosomal sorting motifs has established robust
transport assays for several lysosomal transporters (9, 25, 31).



















Ala Asp Gly LysLeu MetAsn Gln Ser Trp Tyr











transp: Si LY PQ



















Si LY PQ Si LY PQ Si LY PQ





Si: sialin; LY:LYAAT1; PQ: PQLC2; S7: SNAT7 









Fig. 1. Live-cell assay reveals that SNAT7 selectively exports asparagine and glutamine from lysosomes. (A) Principle of the TFEB-based assay. (Left) In un-
treated HeLa cells, the transcription factor TFEB mainly localizes to the cytosol. (Center) Treating cells with an amino acid (AA) ester results in intralysosomal
overload of the corresponding amino acid, which in turn induces TFEB translocation to the nucleus. (Right) Overexpression of a lysosomal transporter that
exports the amino acid out of lysosomes reduces lysosomal stress and, consequently, TFEB nuclear translocation. (B) Proof-of-concept experiment. HeLa cells
were transiently cotransfected with plasmids encoding mRFP-TFEB and one of the three well-characterized lysosomal transporters fused to EGFP, sialin (Si),
LYAAT1 (LY), and PQLC2 (PQ), which export sialic acid, alanine, and lysine, respectively, from lysosomes. In the case of sialin, we used a nontransporting
mutant (P334R) to serve as a negative control. Two days after transfection, cells were treated with 100 mM sucrose or with the indicated amino acid esters at
an optimal concentration (Results and Materials and Methods) for 2 h before fixation. The mRFP-TFEB intracellular localization (cytosolic, nuclear, or mixed)
was determined under a fluorescence microscope, as shown in the photograph, for at least 50 EGFP-positive cells per condition. (Scale bar: 10 μm.) The graph
shows the mean outcome of the number of experiments indicated on the bars. Treating cells with sucrose or amino acid esters induces nuclear translocation
of TFEB in ∼50% of cells. However, TFEB translocation was reduced to 25% and 10%, respectively, in LYAAT1- and PQLC2-expressing cells treated with an
ester of a translocated amino acid (alanine and lysine, respectively). (C) HeLa cells transiently expressing mRFP-TFEB and either rPQLC2-EGFP (PQ) or EGFP-
mSNAT7 (S7) were treated with sucrose or one of the indicated amino acid esters for 2 h before fixation, and the TFEB localization measurement was
performed as in B. The graph displays the mean outcome of three independent experiments. SNAT7 overexpression selectively decreases the lysosomal stress
induced by asparagine and glutamine overload. Error bars represent SD. P values are shown above the bars.
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Fig. 2. SNAT7 is the major lysosomal transporter for glutamine and asparagine. (A) Genomic sequences of SNAT7 KO HeLa cell clones generated by the CRISPR/
Cas9 method. The WT protein sequence of the targeted region is shown at the top. Protospacer adjacent motif (PAM) sequences are indicated in red, and target
specific guide sequences are indicated in blue. The two KO clones display homozygous disruption of the SLC38A7 gene: a 26-bp deletion and a 19-bp deletion +
205-bp insertion (ins) for clones 2.22 and 1.24, respectively. The control clone (CT2) shows nomodification relative to the HeLa cell line (CL). (B) Characterization of
the anti-hSNAT7 antibody by Western blot. SNAT7 appears as a strong 40-kDa band (red arrow) detected in lysates from WT, but not KO, HeLa cells. (C) Scheme
for subcellular fractionation of HeLa cells. Centrifugation is expressed as 1,000 × g × min. L, light mitochondrial fraction; M, heavy mitochondrial fraction;
N, nuclear fraction; P, peroxisomal and microsomal fraction; S, soluble fraction; MLPS, LPS and PS, supernatants containing the corresponding fractions.
(D) Fractions from differential and isopycnic centrifugations were analyzed for SNAT7 immunoreactivity and for diverse organellar markers by Western blot and
enzymatic measurements, respectively. Equal protein amounts were loaded on each lane of the blots shown. β-Galactosidase was used as a lysosomal marker
(other cell compartments are shown in Fig. S3). For the differential centrifugation, graphs show the enrichment factor (Relative Specific Signal) of the protein of
interest against the percentage of total proteins recovered in each fraction. For isopycnic centrifugation, the frequency (Materials and Methods) of the protein of
interest is plotted against sucrose density. (E) Principle of the countertransport assay of SNAT7. Lysosomes partially purified from HeLa cells are selectively loaded
with glutamine using glutamine-tert-butyl (Gln-Bu) ester. After washing, fractions are incubated with [3H]Gln, which accumulates into lysosomes in exchange for
intralysosomal glutamine. (F) SNAT7 mediates lysosomal countertransport of glutamine. Lysosome-enriched fractions, prepared from WT (CT2 clone, black
squares) or SNAT7 KO (clone 1.24, red squares) HeLa cells, were preloaded with Gln, washed, and incubated with [3H]Gln for diverse durations. [3H]Gln uptake,
determined by filtration and scintillation counting, increased linearly over time in a SNAT7-dependent manner. This uptake occurred in lysosomes as lysosomal
lysis induced by 10 mM GME (arrow) released the radioactivity. A representative experiment (exp.; Left) and average normalized kinetics from four lysosome
preparations (prep.; Right) are shown. P value is shown only for the earliest time point. (G) [3H]Gln countertransport was assayed in fractions from WT HeLa cells
(black) or SNAT7 KO clones transiently expressing (green), or not (red), mEGFP-SNAT7. Uptake was measured in triplicates at 0 min (open bars) or 30 min before
(solid bars) or after (hatched bars) lysosomal lysis. Overexpression of mSNAT7 partially rescued glutamine uptake in SNAT7 KO lysosomes. A representative ex-
periment (Left, mean ± SD of triplicate measurements) and average normalized values from six independent experiments performed on distinct lysosome
preparations (Right) are shown.


































However, mutation of the candidate sorting motifs tested (21-
ERARLL-26 and 115-YQEV-118, mouse sequence numbering),
either alone or in combination, did not alter SNAT7 localization.
We, thus, studied SNAT7 activity in isolated lysosomes by the
ester loading/countertransport technique used in the 1980s to
characterize most lysosomal amino acid transport activities (32).
In this approach, lysosomes from a crude subcellular fraction are
selectively loaded with a specific amino acid using an ester pre-
cursor, similar to the approach used above in our TFEB-based
assay. Amino acid-loaded and unloaded lysosomes are then in-
cubated with a radiolabeled free amino acid to measure their
capacity to accumulate the radiotracer. Although most lysosomal
amino acid transporters export their substrate from the organelle
under physiological conditions, they accumulate the external
amino acid in exchange for the internal one in this artificial set-
ting (Fig. 2E) owing to a hallmark property of transporters known
as transstimulation. This property directly results from the
alternating-access mechanism of secondary transporters (33). In-
deed, transporters operate by alternately exposing their substrate-
binding site to one or the other side of the membrane. Under
normal conditions, the transporter visits the whole set of inward/
outward conformations and empty/loaded binding states.
However, when lysosomes are artificially loaded with a high-
substrate concentration, the inward and outward empty states
can be bypassed, with the transporter thus shuttling back and
forth between the two substrate-loaded conformations to ex-
change internal amino acids for the external radiotracer
(Fig. 2E). Such artificially induced exchange reaction is called
“countertransport.”
To test whether this countertransport technique could detect
the transport activity of SNAT7, we prepared a HeLa cell frac-
tion enriched in lysosomes and preloaded these organelles with
glutamine using glutamine-tert-butyl ester. After washing, frac-
tions were incubated with L-[3H]glutamine and the radioactivity
accumulated into membrane vesicles was measured using a fil-
tration assay. [3H]Glutamine accumulated linearly over time into
glutamine-loaded, but not glutamine-empty, fractions from WT
HeLa cells and control Cas9 clones (Fig. 2F and Fig. S4A). Re-
markably, inactivation of SLC38A7 by genome editing decreased
this countertransport by ∼90%, showing that it is carried by native
SNAT7. To confirm that the observed [3H]glutamine accumula-
tion was contributed by lysosomes, 10 mM glycine methyl ester
(GME), a concentration causing a selective osmotic stress and
disruption of lysosomes (34), was added at the end of the uptake
period. In agreement with the lysosomal localization of SNAT7,
this treatment fully released the [3H]glutamine accumulated into
WT and control cellular fractions (Fig. 2 F andG). We considered
the possibility that SNAT7-negative lysosomes might have lost
their countertransport signal because they spontaneously rupture
in our assay. To test this hypothesis, we exposedWT and knockout
(KO) lysosomes to increasing concentrations of GME and assayed
them for disruption using lysosomal enzyme release measurement.
WT and KO lysosomes showed identical vulnerability to GME
(Fig. S4B), thus ruling out this possibility.
To confirm that the glutamine transport activity was associated
with SNAT7, we transiently expressed the mouse protein in KO
HeLa cells. Mouse SNAT7 (mSNAT7) expression restored a ro-
bust [3H]glutamine countertransport signal in these fractions (Fig.
2G). We concluded that SNAT7 is necessary and sufficient for
lysosomal glutamine transport and that it represents the main
glutamine permeation pathway across the lysosomal membrane. It
may be noted that, to the best of our knowledge, lysosomal glu-
tamine transport has not been reported thus far.
Next, we took advantage of the assay to characterize the
transport properties of SNAT7. To examine its substrate selec-
tivity, we tested glutamine-loaded fractions from WT and KO
HeLa cells for their capacity to accumulate diverse tritiated amino
acids. Again, selective lysosomal lysis with GME was used to
discriminate the contributions of lysosomes and contaminating
organelles. In agreement with our TFEB assay data, among the
tested amino acids, only [3H]glutamine and [3H]asparagine accu-
mulated into artificially loaded lysosomes in a SNAT7-dependent
manner (Fig. 3A and Fig. S5). Our results thus strongly diverge
from the broad amino acid selectivity reported by Hägglund et al.
(30). In particular, we could not detect any uptake of [3H]arginine
(Fig. S5), which gave the most significant (P < 0.001) uptake signal
in that study. It should be noted that [3H]histidine was not
transported in our assay (Fig. 3A), thus distinguishing SNAT7
from system N transporters within the SLC38 family.
These experiments informed us about the substrate selectivity
on the cytosolic side of SNAT7. To test the selectivity on the lu-
minal side, we compared the transstimulation properties of diverse
amino acids by treating HeLa cell fractions with distinct esters
before [3H]glutamine countertransport measurement. Again, only
asparagine and glutamine, but not alanine, glutamate, or serine,
transstimulated [3H]glutamine uptake (Fig. 3B). We concluded
that SNAT7 is highly selective for asparagine and glutamine, in
contrast to characterized members of the SLC38 family. Both
amino acids seem to be translocated with similar efficiencies be-
cause their cis and trans effects were highly similar in these ex-
periments (Fig. 3 A and B).
Finally, we examined the bioenergetics properties of SNAT7.
Removal of ATP or inhibition of the V-type H+-ATPase using
bafilomycin A1 abolished [3H]glutamine countertransport
(Fig. 3C), suggesting that although the countertransport assay
does not probe a full transport cycle, the lysosomal V-type
H+-ATPase is required for these partial reactions. To confirm
and characterize the role of the V-ATPase, we applied iono-
phores in the presence of ATP to disrupt, or alter, the lyso-
somal proton electrochemical gradient. The proton ionophore
carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone (FCCP),
which fully disrupts this gradient, abolished [3H]glutamine
countertransport (Fig. 3D). Valinomycin, a potassium ionophore
that disrupts the electrical component of the gradient (mem-
brane potential) but preserves the pH gradient, had no effect.
In contrast, nigericin, an H+/K+ exchanger that disrupts the
pH gradient but preserves the membrane potential, abolished
[3H]glutamine countertransport (Fig. 3D). These data show that
the acidic milieu of lysosomes is required to activate SNAT7. A
potential explanation may be that amino acid transport by SNAT7 is
coupled to proton, thus requiring protonation from the lysosomal
lumen to perform the partial transport reaction measured in
our assay.
Taken together, our TFEB-based live-cell assay and our
countertransport measurements indicate that SNAT7 is an
amino acid transporter highly selective for glutamine and as-
paragine and that it represents the primary export pathway for
these amino acids across the lysosomal membrane.
SNAT7 Is Required for Extracellular Protein-Dependent Proliferation
of Cancer Cells in a Low Free-Glutamine Environment. Cancer cells
require a high level of glutamine for rapid proliferation and survival.
When the extracellular environment does not meet their needs,
several types of cancer use opportunistic cell-nutrition routes, in-
cluding macropinocytosis of extracellular proteins, phagocytosis of
apoptotic corpses, or entosis (cell “cannibalism”) to acquire amino
acids (11). In particular, macropinocytosis of extracellular proteins
is an essential glutamine supply route for the growth of Ras-
transformed cells (12). These opportunistic cell-nutrition routes
converge onto the lysosome and, consequently, onto lysosomal
amino acid exporters. The demonstration that SNAT7 is the pri-
mary lysosomal glutamine transporter thus prompted us to ex-
amine whether it is required for extracellular protein-dependent
growth of cancer cells.
We examined this hypothesis using the MIA PaCa-2 cell line,
derived from a human pancreatic adenocarcinoma, which harbors





















homozygous activating mutations in the Kirsten rat sarcoma viral
oncogene homologue (KRAS) gene (35). In agreement with
Commisso et al. (12), we observed that MIA PaCa-2 cell growth
depends on extracellular free glutamine and that BSA supple-
mentation helps cells grow at low, but not high, free-glutamine
concentrations (Fig. 4A). In contrast, supplementation of the
medium (which lacks asparagine) with 1 mM asparagine did
not rescue cell growth at a low free-glutamine concentration
(0.05 mM), showing that asparagine cannot compensate for the
loss of glutamine. To evaluate the role of SNAT7 in this BSA-
dependent growth, we silenced the SLC38A7 gene in MIA PaCa-
2 cells using three Dicer-substrate short interfering RNAs
(DsiRNAs) targeting hSNAT7 (S7-1, S7-2, and S7-3; TriFECTa
RNAi kit; Integrated DNA Technologies) or, as negative controls,
a DsiRNA with no target sequence in the human genome (CT-1)
and a DsiRNA targeting hypoxanthine phosphoribosyltransferase
1 (CT-2). Individual treatment with each SNAT7-targeted
DsiRNA strongly reduced the hSNAT level upon immunoblot-
ting analysis (Fig. 4B). We thus tested the effect of BSA on the
growth of DsiRNA-treated MIA PaCa-2 cells at a low free-
glutamine concentration (0.2 mM). BSA supplementation (2%)
increased the growth of control cells by 55% over 5 d. In contrast,
this effect was reduced to 18–25% in SLC38A7-silenced cells (Fig.
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Fig. 3. Functional properties of SNAT7. (A) Substrate selectivity on the cytosolic side. Lysosome-enriched fractions from WT and SNAT7 KO HeLa cells were
preloaded with glutamine and assayed for countertransport of various [3H]AA for 30 min. Specific lysosomal uptake, determined based on GME-induced lysis
and SNAT7 dependence (Materials and Methods), was calculated for each substrate and normalized to the [3H]Gln signal. (B) Substrate selectivity on the
luminal side. [3H]Gln countertransport was assayed in lysosome-enriched fractions preloaded with various amino acids using ester precursors. (C) [3H]Gln
countertransport was assayed as in A (ctrl) and either in the absence of ATP (Left) or in the presence of 500 nM bafilomycin A1 (baf; Right). (D) Lysosomal v-
ATPase creates an electrochemical H+ gradient (acidic and positive inside) across the lysosomal membrane. Ionophores can selectively disrupt the chemical [pH
gradient (ΔpH)] or electrical component [voltage gradient (ΔΨ)], or both, as depicted in the scheme. The [3H]Gln countertransport was assayed as in A in the
presence of ATP and 3 μM nigericin (nig), valinomycin (val), or FCCP. Disruption of the pH gradient, but not the voltage gradient, abolished [3H]Gln uptake.
The graph in A shows mean values from two independent experiments. Other graphs are representative experiments of two (B and D) or three (C) exper-
iments performed on distinct lysosome preparations. Error bars represent SD from triplicate measurements.
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Fig. 4. SNAT7 transport activity is required for extracellular protein-dependent growth of cancer cells in a low free-glutamine environment. (A) BSA sup-
plementation (2%) rescues MIA PaCa-2 cell growth in low free-glutamine medium. Growth was measured in triplicate at diverse Gln concentrations by cell
counting and expressed as the mean ratio ± SD between final and initial cell numbers. One representative experiment of three is shown. (B) SNAT7 expression
was silenced in MIA PaCa-2 cells using three distinct SLC38A7-targeted siRNAs (S7-1, S7-2, and S7-3) or two control siRNAs (CT-1 and CT-2) as negative controls.
(Inset) SLC38A7 silencing strongly reduced SNAT7 expression (Western blot). Cells were then transiently transfected with mSNAT7 (S7) or, as a negative
control, a nontransporting sialin construct (Si) and assayed for 2% BSA-dependent growth at 0.2 mM Gln (double arrow in A). SNAT7 silencing decreased, and
mSNAT7 expression rescued, BSA-dependent growth. The graph shows mean value ± SD from three independent experiments. P values for the difference
between control (white bars) and siRNA-treated (gray bar) samples and between siRNA-treated (gray bar) and mSNAT7-reexpressing (gray hatched bar)
samples are displayed in red and black, respectively. (C) SNAT7 expression was abolished in MIA PaCa-2 cells using CRISPR/Cas9 gene editing. The resulting
clones were assayed for BSA-dependent growth as in A. (Left and Center) Graphs show a representative experiment for a WT clone (CTB) and a KO clone (34I)
with (red curve) or without (black) BSA at diverse Gln concentrations. (Right) Graph shows mean BSA-dependent growth value ± SD for three independent
experiments at 0.2 mM Gln for the cell line, one control clone (CTB), and two independent KO clones (34B and 34I). (Inset) Loss of SNAT7 expression was
verified by Western blot. (D, Left) Fluorescence micrographs of HeLa cells expressing N62H and N62Q mEGFP-SNAT7 (green) show a good overlap with the
lysosomal marker LAMP1 (red). (D, Right) Magnifications (2.5×) of the selected areas are shown for each channel. (Scale bar: 20 μm.) (E) Rescue experiments of
[3H]Gln countertransport in HeLa cells. Uptake was assayed in fractions from WT cells (black); SNAT7 KO cells (red, 1.24 clone); and KO cells transiently
expressing WT, N62Q, or N62H mEGFP-SNAT7 (green) as in Fig. 2F. The graph shows mean ± SD values normalized to WT cells from three independent
experiments. P values relative to WT-expressing KO cells are indicated above the bars. The expression of EGFP-mSNAT7 was checked by Western blot. (F)
Rescue experiments of BSA-dependent growth in MIA PaCa-2 cells. WT (white bars) and KO (black) clones transiently expressing sialin (Si) or the indicated
mEGFP-SNAT7 constructs were assayed for 2% BSA-dependent growth in 0.2 mM Gln over 3 d. WT and N62Q mSNAT7 rescue BSA-dependent growth, in
contrast to the transport-defective N62H mutant. The graph shows mean ± SD values from three independent experiments. P values relative to WT-expressing
KO cells are indicated above the bars. The expression of EGFP-mSNAT7 was checked by Western blot.





















BSA for growth in low free-glutamine medium. A similar effect of
SNAT7 was observed with the human ovarian carcinoma A2780 cell
line (Fig. S6B).
To test whether SNAT7 gene silencing affected the BSA-
dependent nutrition route at steps upstream of lysosomal gluta-
mine export, we used the fluorogenic probe DQ-Red-BSA, which
enables monitoring the internalization and lysosomal degradation
of BSA. DQ-Red-BSA is highly conjugated with a fluorophore
that, after uptake by fluid-phase endocytosis or macropinocytosis,
undergoes dequenching on lysosomal proteolysis. SLC38A7 si-
lencing did not alter the capacity of MIA PaCa-2 cells to internalize
and degrade DQ-Red-BSA (Fig. S6C), implying that SNAT7 is
involved downstream of lysosomal proteolysis (i.e., owing to its
location and molecular function) at the lysosomal export step.
To confirm the dependence of BSA-dependent cell growth on
SNAT7, we inactivated the SLC38A7 gene in MIA PaCa-2 cells
using the CRISPR/Cas9 nickase method. The loss of SNAT7 in
selected MIA PaCa-2 cell clones was confirmed by genomic se-
quencing and immunoblotting (Fig. 4C and Fig. S7). Re-
markably, BSA-dependent growth was fully abolished in clones
carrying two loss-of-function SLC38A7 mutations, but not in
control (unedited) clones (Fig. 4C).
Finally, we performed rescue experiments to confirm the role of
SNAT7 in BSA-dependent growth under restricted glutamine
availability and to test whether this role involves its transport ac-
tivity. Transient expression of mSNAT7, which is insensitive to the
hSNAT7-targeted DsiRNAs, rescued BSA-dependent growth of
MIA PaCa-2 cells under low free glutamine to 69% (Fig. 4B).
Similarly, mSNAT7 rescued the BSA-dependent growth of MIA
PaCa-2 cell clones to 23% (Fig. 4F). To examine whether SNAT7
promotes BSA-dependent growth through its amino acid transport
function, we tested the effect of mutations that impact this func-
tion. A highly conserved asparagine present in the first trans-
membrane domain of SLC38 transporters plays a critical role in
amino acid transport (36, 37). Mutation of this residue (N62) to
glutamine or histidine did not affect the lysosomal localization of
transfected mSNAT7 (Fig. 4D). The mutant proteins were, thus,
expressed in HeLa clones devoid of hSNAT7 to assess their
transport activity. Interestingly, N62H strongly reduced lysosomal
glutamine countertransport (10 ± 3% of WT mSNAT7 signal,
n = 3), whereas the conservative mutation N62Q fully preserved
this activity (Fig. 4E). In excellent agreement with these data,
N62Q mSNAT7 rescued the BSA-dependent growth of MIA
PaCa-2 cells lacking hSNAT7 as efficiently as the WT protein,
whereas the N62H mutation had little effect (only 23 ± 4% of WT
mSNAT7-induced growth, n = 3) (Fig. 4F). The role of SNAT7 in
extracellular protein-dependent growth, thus, clearly correlates
with its amino acid transport activity.
Taken together, our results show that SNAT7 is the primary
export pathway of glutamine and asparagine from the lysosome
and that its transport activity is essential to supply extracellular
protein-derived glutamine to cancer cells when free glutamine is
at an insufficient level in their environment.
Discussion
In this study, we provide biochemical and functional evidence for
the lysosomal localization of native SNAT7, thus strengthening
our former proteomic (native SNAT7) and fluorescence mi-
croscopy (GFP-tagged SNAT7) evidence (19). First, in HeLa
cells submitted to two different subcellular fractionation methods
(differential and isopycnic centrifugations), native SNAT7 mainly
codistributes with a lysosomal marker. Second, our countertran-
sport assay combined with gene-editing experiments shows that
the transport activity of SNAT7 is affected by prior incubation
with amino acid esters, a treatment known to load selectively or, at
high concentration, to disrupt lysosomes in crude subcellular
fractions (32). Finally, this transport activity requires an acidic
lysosomal lumen, implying that SNAT7 is not active before its
delivery to endosomes and lysosomes, and that a minor presence,
if any, of SNAT7 at the plasma membrane should not significantly
contribute to amino acid homeostasis in cells living in a neutral
environment. It should be stressed that although luminal acidity
stimulated lysosomal [3H]glutamine uptake under the artificial
conditions of our countertransport assay, our in situ TFEB-based
assay clearly shows that SNAT7 operates in the export direction in
live cells. A very recent proteomic study of multiple subcellular
compartments from rat liver also identified lysosomes as the ma-
jor, if not exclusive, cellular location of SNAT7 (38).
We also provide a detailed characterization of the transport
activity of SNAT7. In particular, we show both in an indirect live-
cell assay and in direct flux measurements that SNAT7 is highly
selective for glutamine and asparagine, in marked contrast to the
broad amino acid selectivity reported by an earlier study (30).
The most likely reason for this discrepancy is the very low
background-level signals observed with the whole-cell Xenopus
oocyte assay used by Hägglund et al. (30), which did not provide
reliable signals in our attempts to replicate these data.
Moreover, our gene knock-down and KO experiments indicate
that, at least in two cell types, SNAT7 is the primary permeation
pathway for glutamine (HeLa and Mia PACA-2) and asparagine
(HeLa) across the lysosomal membrane. Therefore, although other
candidate lysosomal glutamine transporters have been reported (15,
16, 19), their contribution may be negligible or restricted to specific
cell types with low SNAT7 levels. SNAT4, a neutral amino acid
transporter (39), has been detected in the liver lysosomal membrane
with a high spectral index, a parameter reflecting a strong association
with lysosome-enriched fractions, in our earlier proteomic study (19).
However, its transport activity at the plasma membrane requires an
alkaline extracellular pH, with no detectable activity at pH ≤ 6 (39),
in contrast to the strong acidity of the topologically equivalent ly-
sosomal lumen. The presence of SNAT4 in liver lysosomes may thus
reflect its abundance in this tissue and its turnover in the endocytosis
pathway, rather than an active transport role at the lysosomal
membrane. SNAT9 is another SLC38 protein found in the lysosome,
which participates in the amino acid-sensing machinery that regulates
mTORC1 at the lysosomal surface (15, 16, 18). Flux measurements in
reconstituted liposomes showed that SNAT9 transport activity has a
broad selectivity for amino acids, including glutamine and asparagine
(15, 16). However, the transport activity measured in this assay was
extremely slow (15, 16), suggesting that SNAT9 may act as a trans-
ceptor (17) rather than a bona fide transporter. Moreover, the
functional interaction of SNAT9 with mTORC1 indicates a selective
role in transmitting arginine levels, rather than the levels of other
amino acids, to mTORC1 (16). The presence of SNAT9 in the ly-
sosomal membrane thus does not challenge our conclusion that
SNAT7 is the predominant lysosomal transporter for asparagine
and glutamine.
Conversely, because SNAT7 belongs to the same protein
family as SNAT9, it may be asked whether SNAT7 can act as a
transceptor signaling amino acid levels to mTORC1 in addition
to its bona fide transport function. Two lines of evidence argue
against such a possibility. First, alignment of the SNAT7 and
SNAT9 amino acid sequences (Fig. S8) shows that SNAT7 lacks
a large part of the N-terminal cytosolic domain responsible for
the physical interaction of SNAT9 with the Ragulator complex
and the Rag GTPases that recruit mTORC1 to the lysosomal
surface (15, 16, 18). Moreover, five of six identified residues that
are critical for this interaction (16) are not conserved in the
SNAT7 sequence (Fig. S8). Second, Ragulator or Rag pull-down
experiments do not precipitate SNAT7, in contrast to SNAT9
(15). Therefore, although the two lysosomal SLC38 transporters
both contribute to intracellular amino acid homeostasis, they
seem to play quite distinct roles in either amino acid sensing
(SNAT9) or the supply of cytosolic amino acids (SNAT7) de-
rived from intracellular (autophagy) and extracellular (macro-
pinocytosis and phagocytosis) stores.


































Metabolic reprogramming is a hallmark of cancer cells, and it is
required for both oncogenic transformation and tumor develop-
ment (11, 40). In addition to the well-known Warburg effect, this
metabolic reprogramming includes an increased consumption of
glutamine, which is used as a nitrogen donor for nonessential
amino acid and nucleobase synthesis and as a carbon donor to
replenish TCA cycle intermediates (anaplerosis) for energy pro-
duction and cellular redox homeostasis (11, 40, 41). Consequently,
many cancer cells are addicted to glutamine. Glutamine is usually
supplied as a free amino acid by the blood flow, but when the
vasculature is compromised, as in the tumor core, cancer cells
have evolved alternative strategies to acquire amino acids, in-
cluding macropinocytosis and lysosomal degradation of extracel-
lular proteins as observed, for instance, in pancreatic ductal
adenocarcinoma (11, 12, 42). Our study extends this picture by
identifying SNAT7 as a key protein supplying extracellular
protein-derived glutamine into the cytosol.
Ras-activating mutations are known to stimulate macropinocytotic
uptake of extracellular proteins (12, 42, 43), thus explaining the key
role of SNAT7 in the extracellular protein-dependent growth of
MIA PaCa-2 cells (Fig. 4). Macropinocytosis is also stimulated by
Src-activating mutations (44). Surprisingly, although A2780 cells do
not carry such mutations, they also use extracellular proteins in a
SNAT7-dependent manner to grow in low free-glutamine medium
(Fig. S6B), albeit to a lesser extent thanMIA PaCa-2 cells. This finding
suggests that internalization of extracellular proteins and SNAT7-
mediated supply of protein-derived glutamine may have a broader
significance than generally anticipated, with either strong or partial
dependence on this nutrition pathway depending on its relative level
compared with glutamine biosynthesis. Inhibiting SNAT7 may thus
provide a novel type of anticancer therapy for Ras-activated, Src-
activated, and possibly other types of cancers characterized by an in-
creased consumption of glutamine and poorly vascularized tumors.
Although SNAT7 efficiently exports both glutamine and as-
paragine from the lysosome, the dependence of extracellular
protein-dependent growth on SNAT7 is most probably associated
with its glutamine export activity because asparagine does not
rescue MIA PaCa-2 cell growth in low free-glutamine medium.
This selective dependence of cell growth on glutamine supply may
arise from the hub-like role of this amino acid in mammalian cell
metabolism. Indeed, glutamine is a precursor for several impor-
tant metabolic pathways (nucleotide, hexosamine, and glutathione
synthesis and replenishment of Krebs cycle intermediates) in ad-
dition to protein synthesis. Moreover, in mammals, the nitrogen
donor for asparagine synthesis is glutamine instead of ammonia.
Therefore, asparagine biosynthesis depends on glutamine, but the
converse is not true.
Interestingly, the pathogenesis of pancreatic ductal adenocarci-
noma also involves a transcriptional program, which is induced by
constitutive activation of TFEB and related transcription factors
(MITF, TFE3), and which up-regulates autophagy and lysosomal
biogenesis to maintain intracellular amino acid pools under condi-
tions of nutrient deprivation, thereby promoting cell survival (45). If
glutamine availability significantly contributes to this survival re-
sponse, for instance, by maintaining the cellular redox balance (41),
inhibiting SNAT7 might trigger cell death, in addition to preventing
macropinocytosis-dependent growth, because of the key role of ly-
sosomes at the intersection of the macropinocytosis and autophagy
pathways. The role of SNAT7 as a primary route for (auto)lysosomal
glutamine export thus makes it an attractive potential therapeutic
target for this extremely aggressive type of cancer.
Materials and Methods
Cell Culture and DNA Transfection. Human cell lines were used in accor-
dance with the regulations and guidelines from the French Ministry of Higher
Education and Research (CODECOH). HeLa, A2780, and Mia-PaCa2 cells were
grown in DMEM supplemented with 10% FBS, 50 μg·mL−1 streptomycin, and
50 U·mL−1 penicillin (“complete medium”; all products from GIBCO). They were
kept in a humidified atmosphere at 37 °C with 5% CO2. For CRISPR/Cas9 ge-
nome edition and rescue experiments, HeLa and Mia-PaCa2 cells were trans-
fected using Lipofectamine 2000 (Thermo Fisher Scientific) and Lullaby
(OzBiosciences), respectively, according to the manufacturers’ instructions. For
the TFEB-based and countertransport assays of lysosomal transporters, HeLa
cells were transfected by electroporation as described elsewhere (9).
TFEB-Based Assay of Lysosomal Amino Acid Transport. HeLa cells were elec-
troporated with two plasmids, one encoding mRFP-hTFEB and another
encoding a lysosomal transporter: EGFP-mSNAT7, EGFP-LYAAT1, rPQLC-EGFP
(25), or EGFP-sialin P334R (9). They were then seeded onto coverslips in 24-well
plates (160,000 cells per well) and grown for 48 h. Cells were then treated for
2 h at 37 °C in complete culture medium supplemented with 25 mMHepes (pH
7.4) and the following amino acid esters: 3 mM alanine methyl-ester, 10 mM
aspartate dimethyl-ester, 4.5 mM glycine methyl-ester, 40 mM lysine methyl-
ester, 1.7 mM leucine methyl-ester, 6 mM methionine methyl-ester, 27 mM
asparagine methyl-ester, 3.75 mM glutamine tert-butyl-ester, 7 mM serine
methyl-ester, 1 mM tryptophan methyl-ester, and 3.7 mM tyrosine methyl-
ester (all from Sigma, except glutamine tert-butyl-ester from Santa Cruz Bio-
technology). Cells were then washed in PBS++ (supplemented with 0.1 mM
CaCl2 and 0.1 mMMgCl2), fixed with 4% paraformaldehyde, washed in 50 mM
NH4Cl, and rinsed in PBS
++, before mounting coverslips onto glass slides using
Fluoromount-G (Southern Biotech). Cells were first visualized under epifluor-
escence microscopy in the green channel to select at least four different fields
and 50 transporter-expressing cells for each condition and then visualized in
the red channel to determine and categorize (Fig. 1B) the distribution of
mRFP-hTFEB. In proof-of-concept experiments, samples were categorized
identically by two independent observers.
Countertransport Measurements. Lysosome-enriched fractions were prepared
fromHeLa cells at 4 °C essentially as described elsewhere (46), using pipette tips
cut obliquely to minimize lysosome breakage. A total of 22.5 × 106 cells were
harvested with trypsin, washed, and resuspended in 1.1 mL of purification
buffer (250 mM sucrose, 10 mM acetic acid, 10 mM ethanolamine, 2.5 mM KCl,
1 mM EDTA, and 5 mM ATP adjusted to pH 7.4 with NaOH). Cells were broken
by 50 passages through a 27-gauge × 3/4 needle and centrifuged at 750 × g for
10 min. The supernatant was kept, and the pellet resuspended in 1.1 mL of
purification buffer was centrifuged again at 750 × g for 10 min. The two
supernatants were pooled and centrifuged at 1,500 × g for 15 min, and the
resulting supernatant was centrifuged at 20,000 × g for 15 min. The resulting
pellet was resuspended in 110 μL of purification buffer supplemented with
amino acid esters (same concentrations as in the TFEB-based assay) and in-
cubated at 25 °C for 15 min. The mix was split into four tubes of 25 μL and
centrifuged at 20,000 × g for 15 min. Each pellet was resuspended in 400 μL of
purification buffer supplemented with 4 μCi of 3H-amino acid (PerkinElmer;
final concentration 200 nM). When mentioned, 3 μM nigericin, FCCP, or vali-
nomycin (all from Sigma) was added. Mixes were then split into seven he-
molysis tubes (50 μL per tube) kept on ice. One mix was directly filtered
(discussed below) to determine background radioactivity. The six remaining
mixes were incubated at 25 °C for 30 min. Three of them were immediately
filtered, whereas three others were incubated further for 10 min in the
presence of 10 mM glycine-methyl-ester specifically to disrupt the lysosomes
before filtration. The accumulated radioactivity was determined by diluting
mixes with 3 mL of chilled PBS and filtration onto a 0.45-μm pore nitrocellulose
membrane (HAWP02500; Millipore), followed by three washes with chilled PBS.
The radioactivity retained on filters was determined using a Tri-Carb 2100 TR
liquid scintillation analyzer (Packard). In Fig. 3A, specific lysosomal uptake,
determined based on GME-induced lysis and SNAT7 dependence, was calcu-
lated as (uptake @ 30 min − uptake after lysosomal lysis)WT − (uptake @
30 min − uptake after lysosomal lysis)KO.
Growth Assays. At day 1, MIA PaCa-2 or A2780 cells were seeded in 24-well
plates at 15,000 or 60,000 cells per well in DMEM without glutamine sup-
plemented with penicillin, streptomycin, Hepes-Na+ (pH 7.4) (25 mM) and
dialyzed FBS (10%; Gibco). Medium was supplemented with various con-
centrations of glutamine (Sigma) and fatty acid-free BSA (reference no.
126609; Calbiochem) at the indicated concentrations. Medium was replaced
at days 2 and 3. At day 4, cells were counted using an automatic cell counter
(Beckman Coulter).
Statistics. One-way ANOVA with the post hoc Tukey’s test was performed
with GraphPad Prism. Additional information is provided in SI Materials and
Methods (16, 28, 29, 47).
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